国际介入与多学科治疗肿瘤学会年会暨第九届肝癌介入与多学科诊疗会议

12:15-13:15 | Art of Interventional Therapy for Liver Cancer

Moderator：

时间	题目	讲者	单位
12:15-12:20	Opening Remarks Gao-Jun Teng Zhongda Hospital, Southeast University, China
12:20-12:35	TACE with epirubicin-loaded microspheres for HCC: A prospective, single-arm, multicenter, phase 2 study (STOPPER trial)	Hai-Dong Zhu	Zhongda Hospital, Southeast University, China
12:35-12:45	Efficacy & Safety of TANDEM Microspheres in Super-selective Transarterial Chemoembolization	David Hahn
12:45-12:55	Redefining the Precision Image-guided Solution for Interventional Oncology in Liver Cancer Treatment	Simone Henrichs
12:55-13:15	Panel Discussion Ming Chao The Second Affiliated Hospital of Zhejiang University Medical College, China / Xu Zhu Beijing Cancer Hospital, China

13:30-14:40 | Current Status and Future Synergistic Opportunities: Interventional Oncology and Immuno-oncology for Primary Liver Cancer I

Moderator：

时间	题目	讲者	单位
13:30-13:42	MDT strategy for management of primary liver cancer	Ming Kuang	The First Affiliated Hospital, Sun Yat-Sen University, China
13:42-13:54	Personalized treatment for HCC – different tumors, different treatments	Edward W. Lee	David Geffen School of Medicine at UCLA, USA
13:54-14:06	Current status of HCC management in South Korea	Hyun Ki Yoon	Asan Medical Center, University of Ulsan College of Medicine, Korea
14:06-14:18	All about extrahepatic collaterals in TACE for HCCs	Sangjoon Park	Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Korea
14:18-14:30	Chinese Expert Consensus on Conversion and Perioperative Management of Hepatocellular Carcinoma(HCC)	Jian Zhou	Zhongshan Hospital, Fudan University, China
14:30-14:40	Q & A

14:40-16:00 | Current Status and Future Synergistic Opportunities: Interventional Oncology and Immuno-oncology for Primary Liver Cancer II

Moderator：

时间	题目	讲者	单位
14:40-14:52	Pressure-enabled delivery and the future of locoregional immunotherapy	Jon C. Davidson	University Hospitals Cleveland Medical Center, USA
14:52-15:04	The dynamic of T cell responses correlated with the anti-PD-1 adjuvant therapy after RFA for patients with HCC	Yong-Hong Zhang	Beijing YouAn Hospital, Capital Medical University, China
15:04-15:16	Establishing and harmonizing systemic and locoregional therapy in HCC	David M. Liu	Vancouver General Hospital, Canada
15:16-15:28	Immunotherapy for hepatocellular carcinoma	George Lau	Humanity and Health Medical Group, HKSAR, China
15:28-15:40	The role of TACE vs DEB-TACE in treating HCC: Do we need elution?	Ziv J. Haskal	University of Virginia School of Medicine, USA
15:40-16:00	Q&A

16:00-17:00 | Managing a Long and Winding Road: Liver Metastases

Moderator：

时间	题目	讲者	单位
16:00-16:12	Percutaneous liver tumors ablation: Current indications and evidence	Eduardo Houghton	University of Buenos Aires, Argentina
16:12-16:24	ctDNA Test Application in MRD for Colorectal Cancer	Gong Chen	Sun Yat-sen University Cancer Center, China
16:24-16:36	DSM transarterial chemosaturation vs DEB TACE in liver metastases: Which works best?	Alex Tang Ah Lak	Subang Jaya Medical Centre, Malaysia
16:36-16:48	Chemoembolization in mCRC	Roberto Iezzi	Università Cattolica del Sacro Cuore, Italy
16:48-17:00	DEBIRI combined with HAIC for colorectal cancer liver metastases	Xu Zhu	Beijing Cancer Hospital, China

17:00-18:10 | Shaping the Future of Ablation for Solid Tumors

Moderator：

时间	题目	讲者	单位
17:00-17:12	The standard and consensus of thermal ablation for thyroid nodules	Dong Xu	Zhejiang Cancer Hospital, China
17:12-17:24	Treating HCC with cryoablation	Min Woo Lee	Samsung Medical Center, Korea
17:24-17:36	Ultrasound guided microwave ablation for adenomyosis of the uterus	Hui-Xiong Xu	Zhongshan Hospital，Fudan University, China
17:36-17:48	Different energy ablation in tumor treatment	Yue-Yong Xiao	The First Medical Center of Chinese PLA General Hospital, China
17:48-18:00	Ultrasound-guided ablation for liver cancer	Xiao-Yan Xie	First Affiliated Hospital of Sun Yat-sen University, China
18:00-18:10	Q ＆ A

2024-06-07 星期五